ClinicalTrials.gg
CompletedNCT01636778Updated Mar 1, 2016Results posted

Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

A Phase 2 interventional study of SB-497115-GR in Hepatitis C, Chronic, sponsored by GlaxoSmithKline. Completed at 16 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-03-01.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Hepatitis C, Chronic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · GlaxoSmithKline.

Enrollment
10th of 14
45 · median 62
Started
2012
with 1 other
Phase 2
6 of 14
none open now
Registered
11th of 14
by date

Among the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline, this one is the 10th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 11th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to assess the ability of SB-497115-GR to raise platelet counts in thrombocytopenic patients with hepatitis C virus (HCV) infection (platelet count \<80,000 /μL, suggestive of compensated cirrhosis) to a level desirable to initiate antiviral therapy and to assess the ability of SB-497115-GR to maintain platelet counts at a level sufficient to minimise dose reductions of pegylated interferon (Peg-IFN) and ribavirin (RBV) therapy with the expectation that a lower rate of Peg-IFN dose reduction and omission will translate to a higher rate of sustained viral response.

03

Conditions studied

  • Hepatitis C, Chronic

Keywords

  • Thrombocytopenia
  • Hepatitis C, chronic
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject is able to understand and comply with protocol requirements and instructions and is likely to complete the study as planned, as well as provided a written consent.

  • A subject age between ≥20 and \<75 years at time of .
  • A subject who applies to one of the following:

Female subject with non- [i.e., physiologically incapable of becoming pregnant, who: has had a hysterectomy, or had a bilateral oophorectomy (ovariectomy), or had a bilateral tubal ligation, or is for greater than one year].

Female subject with childbearing potential, has a negative urine or serum pregnancy test at screening and within the 24-hour period prior to the first dose of SB-497115-GR, and completely abstains from intercourse or agree to use two of the following acceptable methods of for 14 days before exposure to SB-497115-GR, throughout the clinical trial, and for 24 weeks after completion or premature discontinuation from the study.

Intrauterine device or intrauterine system that meets the effectiveness criteria as stated in the product label.

Male partner sterilization prior to the female subject's entry into the study, and this male is the sole partner for that subject.

Double-barrier contraception (condom with spermicidal jelly, or diaphragm with spermicide).

Male subject with childbearing potential partner completely abstains from intercourse or agree to use condom and diaphragm with spermicide.

  • Subjects who were diagnosed as or compensated liver cirrhosis ( class A) without hepatic encephalopathy, or ascites. If there is a clear cirrhosis, treatment should be given with care as there is a potential of progressing to liver failure.
  • Subjects who, in the opinion of the investigator, are appropriate candidates for Peg-IFN and RBV combination therapy for 48 weeks.
  • HCV positive by TaqMan test at screening.
  • Subject who fulfil all the organ functions below.

Items Values \<80,000 /μL ≥12.0 g/dL* (ANC) ≥1500 /μL* >50 mL/minute Total \<2.0 mg/dL Albumin >3.0 g/dL >60%

*If the investigators consider the values are sufficient to give Peg-IFN/RBV, then a subject can be enrolled upon consulting the Medical Monitor.

Exclusion criteria

Exclusion Criteria:

  • Subject who or did not respond after 48 weeks of Peg-IFN/RBV therapy had been given with sufficient dose previously.
  • Subject with history of IFN (including Peg-IFN) therapy or Peg-IFN/RBV therapy, but could not been treated with optimal Peg-IFN/RBV therapy due to the reasons other than thrombocytopenia.
  • Subject who received IFN therapy (including Peg-IFN), antiviral therapy (excluding oseltamivir phosphate, etc.), immuno-modulatory treatment, radiotherapy or phlebotomy within 3 months (90 days) prior to the first dose of SB-497115-GR.
  • Treatment with an drug within 30 days prior to the first dose of SB-497115-GR or 5 half-lives of that investigational drug (whichever is longer).
  • Subject with decompensated liver disease.
  • Chronic liver disease other than chronic (e.g., hepatitis, alcohol-induced hepatitis, drug-induced hepatitis, etc.).
  • Subject with idiopathic thrombocytopenic purpura or active autoimmune disease.
  • Subject who have had a diagnosed and/or treated within the past 5 years.
  • Subjects who require endoscopic treatment for varices or documented history of bleeding from oesophageal or gastric varices.
  • Any disease condition associated with active bleeding or requiring anticoagulation with heparin or warfarin.
  • Subject with serious cardiac, cerebrovascular, chronic pulmonary disease or interstitial lung disease, or documented history of any of these diseases.
  • Pre-existing cardiac disease (congestive heart failure in Grade III/IV), or arrhythmias known to involve the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a >450 msec or if with bundle brunch block, QTcF >480 msec.
  • Subject with depression, psychiatric disorder requiring treatment or suicidal ideation or suicide attempt history, or history of these.
  • Subject with uncontrolled hypertension (≥160 mmHg systolic or ≥100 mmHg diastolic).
  • Subject with diabetes mellitus that can not be controlled by treatment.
  • Thyroid dysfunction not adequately controlled.
  • Subjects with haemoglobinopathies.
  • History or current condition of seizure disorder.
  • Subject who was positive for (HIV) antibody or Virus (HBV) antigen.
  • Subject with arterial or venous thrombosis history or evidence of portal vein thrombosis on abdominal imaging (e.g., by computerized tomography or magnetic resonance imaging) within 3 months.
  • History of alcohol/drug abuse or dependence.
  • History of clumping that prevents reliable measurement of platelet counts.
  • Subjects planning to have cataract surgery.
  • History of major organ transplantation.
  • Known to SB-497115-GR ingredients, IFN (including Peg-IFN), nucleoside analogues or biological agents (i.e., vaccines).
  • Pregnant or nursing women or a male subject with pregnant partner.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    SB-497115-GR

    investigational product for thrombocytopenia

    Drug: SB-497115-GR

Interventions

  • TPO receptor agonist to increase platelet count

06

What researchers measure

Primary outcomes

  1. Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1

    Participants were assessed for a shift from a baseline platelet count of \<80 Gi/L to a count \>=100 Gi/L during Part 1(up to 9 weeks). Platelet counts were measured by blood draw.

    Time frame: From Baseline up to Week 9 in Part 1

  2. Number of Participants Whose Platelet Counts Maintained at >=50 Gi/L During Part 2

    Participants were assessed for continuously maintaining platelet counts \>=50 Gi/L during Part 2. Platelet counts were measured by blood draw.

    Time frame: From Antiviral Baseline to up to Week 48 in Part 2

Secondary outcomes

  1. Median Platelet Count at the Indicated Time Points in Part 1

    Platelet counts were measured by blood draw

    Time frame: Baseline, Week1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1

  2. Time in Weeks to Achieve Platelet Count >= 100 Gi/L

    Participants were assessed for achieving platelet counts \>=100 Gi/L during Part 1. Platelet counts were measured by blood draw.

    Time frame: From Baseline up to Week 9 in Part 1

  3. Median Platelet Count at the Indicated Time Points in Part 2

    Platelet counts were measured by blood draw

    Time frame: Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2

  4. Median Platelet Count at the Indicated Time Points During Follow-up Period After Part 2

    Platelet counts were measured by blood draw at specified timepoints.

    Time frame: Follow-up (FU) Baseline, FU Week 4, FU Week 12 and and FU Week 24 after Part 2

  5. Minimum Platelet Count on Antiviral Therapy

    Participants were assessed for platelet counts during antiviral therapy in Part 2. Platelet counts were measured by blood draw.

    Time frame: From Antiviral Baseline to up to Week 48 in Part 2

  6. Dose of Eltrombopag That Enabled Initiation of Antiviral Therapy

    Participants received eltrombopag at escalating dosages until a platelet count of \>=100 Gi/L was achieved in Part 1. Platelet counts were measured by blood draw.

    Time frame: From Baseline up to Week 9 in Part 1

  7. Number of Antiviral Therapy Dose Reductions in Part 2

    Number of reductions in Part 2 of either Peg-IFN or RBV. Participants were assigned a score equal to the number of times antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN and/or RBV.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  8. Number of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2

    Participants were assigned a score equal to the number of times their Peg-IFN alpha-2a dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  9. Number of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2

    Participants were assigned a score equal to the number of times their Peg-IFN alpha-2b dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  10. Number of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2

    Participants were assigned a score equal to the number of times their RBV dose of antiviral therapy was reduced (0=no DRs; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of RBV

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  11. Time to First Dose Reduction of Antiviral Therapy in Part 2

    Time to first dose reduction was calucated as the time period from the first dose to the first dose reduction.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  12. Number of Participants Who Discontinued Antiviral Therapy in Part 2

    Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Antviral Therapy was assessed up to 48 weeks in Part 2

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  13. Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2

    Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2a therapy was assessed up to 48 weeks in Part 2

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  14. Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2

    Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2b therapy was assessed up to 48 weeks in Part 2

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  15. Number of Participants Achieving Adherence to Antiviral Therapy in Part 2

    Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  16. Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2

    Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa-2a and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  17. Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2

    Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alpha-2b and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  18. Number of Participants With Sustained Virologic Response (SVR) in Part 2

    Participants with SVR were defined as those with undetectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of treatment period Part 2

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  19. Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2

    RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA between 4 weeks and 12 weeks after antiviral treatment.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  20. Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2

    EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 decrease in HCV RNA or undetectable HCV RNA) after 12 weeks of antiviral treatment. cEVR, a subset of EVR, is defined exclusively as undetectable HCV RNA after 12 weeks of antiviral treatment.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  21. Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2

    ETR is defined as undetectable HCV RNA at the end of Peg-IFN/RBV treatment.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  22. Mean Serum HCV RNA at the Indicated Time Points In Part 2

    The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at Screening, Antiviral Baseline, Part 2 week 4, 12, 24, 36, 48 and at withdrawal.

    Time frame: Screening, Antviral baseline; Week 4, 12, 24, 36, 48, Withdrawal in Part 2

  23. Mean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2

    The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at FU Baseline, FU Week 12 and FU Week 24 during Follow-up Period after Part 2

    Time frame: FU Baseline, FU Week 12 and FU Week 24 after Part 2

  24. Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

    Time frame: From Baseline up to week 9 in Part 1

  25. Number of Participants With Any AE and Any SAE in Part 2

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

    Time frame: From Antiviral Baseline up to Week 48 in Part 2

  26. Number of Participants With Any AE and Any SAE During Follow-up Period After Part 2

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

    Time frame: From FU Baseline up to FU Week 24 after Part 2

  27. Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period

    Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

    Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, and FU Week 24

  28. Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2

    Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

    Time frame: Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2

  29. Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2

    Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed.

    Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2

  30. Mean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period

    The heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24

  31. Mean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2

    The heart rate was measured in participants at the indicated time points. Mean change from Antiviral Baseline was calculated as the value at the indicated time points minus the value at Antiviral Baseline.

    Time frame: Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2

  32. Mean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2

    The heart rate was measured in participants at the indicated time points.

    Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2

  33. Mean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period

    The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24

  34. Mean Change From Baseline in Weight at the Indicated Time Points in Part 2

    The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline; Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2

  35. Mean Weight at the Indicated Time Points During Follow-up Period After Part 2

    The weight of participants was recorded at the indicated time points.

    Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2

  36. Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period

    The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24

  37. Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2

    The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

    Time frame: Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2

  38. Mean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2

    The Body temperature of participants was recorded at the indicated time points..

    Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2

  39. Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc

    The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

    Time frame: Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24

  40. Mean Change From Baseline in BMI at the Indicated Time Points in Part 2

    The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

    Time frame: Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2

  41. Mean BMI at the Indicated Time Points During Follow-up Period After Part 2

    The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.

    Time frame: FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2

  42. Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1

    Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 1. Clinical chemistry parameters included albumin, alkaline phosphatase (ALP), ALT, aspartate amino transferase (AST), total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From Baseline up to Week 9

  43. Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2

    Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From Antiviral Baseline up to Week 48

  44. Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2

    Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From FU Week 4 to FU Week 24

  45. Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1

    Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 1 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From Baseline up to Week 9

  46. Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2

    Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From Antiviral Baseline up to Week 48

  47. Number of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2

    Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From FU Week 4 to FU Week 24

  48. Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period

    Urinalysis parameters included: urine bilirubin (UB), urine occult blood (UOB), urine glucose (UG), urine ketones (UK), pH, urine protein (UP), urine specific gravity (USG) and urine urobilinogen (UU). The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as 1+, (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.

    Time frame: Screening, Baseline, Week 1, 2, 3, 4, 7, 8, Withdrawal, FU Week 24

  49. Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2

    Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.

    Time frame: Antiviral Baseline,Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal

  50. Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2

    Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.

    Time frame: FU Baseline and FU Week 24

  51. Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points

    The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.

    Time frame: Screening, Antiviral Baseline, Week 12, 24, 36, 48, Withdrawal

  52. Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2

    The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.

    Time frame: FU Baseline and FU Week 24

  53. Number of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points

    Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, withdrawal (WD)/completion (comp). Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).

    Time frame: Baseline; Week 24, Week 48, Withdrawal/Completion

  54. Number of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2

    Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).

    Time frame: FU Week 24

  55. Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study

    Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, WD/comp. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).

    Time frame: Baseline; Week 24, Week 48, Withdrawal/Completion

  56. Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2

    Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).

    Time frame: FU Week 24

07

Results

Posted Feb 23, 2015

Participant flow

Participants with chronic hepatitis C (CHC) or compensated liver cirrhosis, who cannot start polyethylene glycol (Peg)-interferon (IFN)/ribavirin (RBV) therapy due to thrombocytopenia (platelet count \<80 giga (10\^9) cells per liter (Gi/L).

Pre-Antiviral Treatment Period (Part 1)
Participant flow — Pre-Antiviral Treatment Period (Part 1)
MilestoneEltrombopag Dose Escalation: Part 1Eltrombopag + Antiviral Therapy: Part 2Eltrombopag + Antiviral Therapy: Follow-up Period After Part
Started4500
Completed4100
Not completed400
Withdrew: Protocol violation300
Withdrew: Protocol-defined stopping criteria100
Antiviral Treatment Period (Part 2)
Participant flow — Antiviral Treatment Period (Part 2)
MilestoneEltrombopag Dose Escalation: Part 1Eltrombopag + Antiviral Therapy: Part 2Eltrombopag + Antiviral Therapy: Follow-up Period After Part
Started0410
Completed0310
Not completed0100
Withdrew: Adverse event070
Withdrew: Protocol violation010
Withdrew: Physician decision020
Follow-up Period After Part 2
Participant flow — Follow-up Period After Part 2
MilestoneEltrombopag Dose Escalation: Part 1Eltrombopag + Antiviral Therapy: Part 2Eltrombopag + Antiviral Therapy: Follow-up Period After Part
Started0041
Completed0037
Not completed004
Withdrew: Other001
Withdrew: Not entered fu period after withdrawal001
Withdrew: Withdrawal by subject002

Outcome measures

PrimaryNumber of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1

Participants were assessed for a shift from a baseline platelet count of \<80 Gi/L to a count \>=100 Gi/L during Part 1(up to 9 weeks). Platelet counts were measured by blood draw.

Time frame:
From Baseline up to Week 9 in Part 1
Reported as:
Number · Participants
Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1
ParticipantsEltrombopag Dose Escalation: Part 1
Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 143
PrimaryNumber of Participants Whose Platelet Counts Maintained at >=50 Gi/L During Part 2

Participants were assessed for continuously maintaining platelet counts \>=50 Gi/L during Part 2. Platelet counts were measured by blood draw.

Time frame:
From Antiviral Baseline to up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants Whose Platelet Counts Maintained at >=50 Gi/L During Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants Whose Platelet Counts Maintained at >=50 Gi/L During Part 236
Statistical analysis
  • Eltrombopag + Antiviral Therapy: Part 2 · Percentage: 88 · 95% CI 74 to 96
SecondaryMedian Platelet Count at the Indicated Time Points in Part 1

Platelet counts were measured by blood draw

Time frame:
Baseline, Week1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1
Reported as:
Median · 10^9 Cells Per Liter (Gi/L)
Median Platelet Count at the Indicated Time Points in Part 1
10^9 Cells Per Liter (Gi/L)Eltrombopag Dose Escalation: Part 1
Baseline, n=4563.0 (34 to 78)
Week 1, n=4374.0 (36 to 108)
Week 2, n=36100.0 (43 to 248)
Week 3, n=1797.0 (48 to 153)
Week 4, n=9104.0 (48 to 137)
Week 5, n=487.0 (49 to 132)
Week 6, n=383.0 (53 to 93)
Week 7, n=397.0 (56 to 103)
Week 8, n=279.0 (63 to 95)
Week 9, n=1100.0 (100 to 100)
Withdrawal, n=496 (48 to 115)
SecondaryTime in Weeks to Achieve Platelet Count >= 100 Gi/L

Participants were assessed for achieving platelet counts \>=100 Gi/L during Part 1. Platelet counts were measured by blood draw.

Time frame:
From Baseline up to Week 9 in Part 1
Reported as:
Number · Participants
Time in Weeks to Achieve Platelet Count >= 100 Gi/L
ParticipantsEltrombopag Dose Escalation: Part 1
Within 2 Weeks11
Within 4 Weeks25
Within 6 Weeks5
Within 8 Weeks1
Within 9 Weeks0
Greater than 9 Weeks1
SecondaryMedian Platelet Count at the Indicated Time Points in Part 2

Platelet counts were measured by blood draw

Time frame:
Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Reported as:
Median · Gi/L
Median Platelet Count at the Indicated Time Points in Part 2
Gi/LEltrombopag + Antiviral Therapy: Part 2
Antiviral Baseline, n=41114.0 (100 to 248)
Week 1, n=40106.5 (50 to 431)
Week 2, n=40118.0 (58 to 309)
Week 4, n=3789.0 (43 to 126)
Week 6, n=3686.0 (38 to 130)
Week 8, n=3679.5 (53 to 130)
Week 12, n=3680.5 (55 to 161)
Week 16, n=3679.5 (49 to 128)
Week 20, n=3675.5 (54 to 119)
Week 24, n=3676.5 (29 to 128)
Week 28, n=3475.0 (49 to 128)
Week 32, n=3473.0 (30 to 161)
Week 36, n=3476.0 (43 to 148)
Week 40, n=3380.0 (48 to 135)
Week 44, n=3179.0 (37 to 172)
Week 48, n=3182.0 (49 to 170)
Withdrawal, n=10102.0 (54 to 207)
SecondaryMedian Platelet Count at the Indicated Time Points During Follow-up Period After Part 2

Platelet counts were measured by blood draw at specified timepoints.

Time frame:
Follow-up (FU) Baseline, FU Week 4, FU Week 12 and and FU Week 24 after Part 2
Reported as:
Median · Gi/L
Median Platelet Count at the Indicated Time Points During Follow-up Period After Part 2
Gi/LEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, n=3486.5 (36 to 184)
FU Week 4, n=3482.5 (43 to 645)
FU Week 12, n=3470.0 (37 to 154)
FU Week 24, n=3163.0 (41 to 145)
SecondaryMinimum Platelet Count on Antiviral Therapy

Participants were assessed for platelet counts during antiviral therapy in Part 2. Platelet counts were measured by blood draw.

Time frame:
From Antiviral Baseline to up to Week 48 in Part 2
Reported as:
Number · Participants
Minimum Platelet Count on Antiviral Therapy
ParticipantsEltrombopag + Antiviral Therapy: Part 2
<25 Gi/L0
>=25 to <50 Gi/L5
>=50 to <100 Gi/L34
>=100 to <150 Gi/L2
>=150 to <200 Gi/L0
>=200 to <400 Gi/L0
>= 400 Gi/L0
SecondaryDose of Eltrombopag That Enabled Initiation of Antiviral Therapy

Participants received eltrombopag at escalating dosages until a platelet count of \>=100 Gi/L was achieved in Part 1. Platelet counts were measured by blood draw.

Time frame:
From Baseline up to Week 9 in Part 1
Reported as:
Number · Participants
Dose of Eltrombopag That Enabled Initiation of Antiviral Therapy
ParticipantsEltrombopag Dose Escalation: Part 1
Eltrombopag 0 mg1
Eltrombopag 12.5 mg25
Eltrombopag 25 mg13
Eltrombopag 37.5 mg0
Eltrombopag 50 mg2
Did not initiate antiviral therapy4
SecondaryNumber of Antiviral Therapy Dose Reductions in Part 2

Number of reductions in Part 2 of either Peg-IFN or RBV. Participants were assigned a score equal to the number of times antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN and/or RBV.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Antiviral Therapy Dose Reductions in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
0 DR8
1 DR9
2 DR10
3 DR3
4 DR2
5 DR1
7 DR3
8 DR1
10 DR2
SecondaryNumber of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2

Participants were assigned a score equal to the number of times their Peg-IFN alpha-2a dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
0 DR4
1 DR6
2 DR4
3 DR1
>3 DR1
SecondaryNumber of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2

Participants were assigned a score equal to the number of times their Peg-IFN alpha-2b dose of antiviral therapy was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of Peg-IFN.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
0 DR16
1 DR2
2 DR4
3 DR0
>3 DR3
SecondaryNumber of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2

Participants were assigned a score equal to the number of times their RBV dose of antiviral therapy was reduced (0=no DRs; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of RBV

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
0 DR14
1 DR12
2 DR9
3 DR3
>3 DR3
SecondaryTime to First Dose Reduction of Antiviral Therapy in Part 2

Time to first dose reduction was calucated as the time period from the first dose to the first dose reduction.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Mean · weeks
Time to First Dose Reduction of Antiviral Therapy in Part 2
weeksEltrombopag + Antiviral Therapy: Part 2
Peg-IFN alfa-2a dose reduction, n=129.44 ± 12.556
Peg-IFN alfa-2b dose reduction, n=96.22 ± 6.944
RBV dose reduction, n=279.16 ± 6.611
SecondaryNumber of Participants Who Discontinued Antiviral Therapy in Part 2

Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Antviral Therapy was assessed up to 48 weeks in Part 2

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants Who Discontinued Antiviral Therapy in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants Who Discontinued Antiviral Therapy in Part 28
SecondaryNumber of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2

Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2a therapy was assessed up to 48 weeks in Part 2

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 21
SecondaryNumber of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2

Dosing discontinuation is defined as the occurrence of stopping the medication. Dosing discontinuation of Peg-IFN alpha-2b therapy was assessed up to 48 weeks in Part 2

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 27
SecondaryNumber of Participants Achieving Adherence to Antiviral Therapy in Part 2

Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants Achieving Adherence to Antiviral Therapy in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants Achieving Adherence to Antiviral Therapy in Part 232
SecondaryNumber of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2

Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alfa-2a and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 214
SecondaryNumber of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2

Adherence to antiviral therapy was defined as receiving at least 80% of the prescribed dose (investigator prescribed) of Peg-IFN alpha-2b and at least 80% of the prescribed dose (investigator prescribed) of RBV, for at least 80% of the planned duration.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 218
SecondaryNumber of Participants With Sustained Virologic Response (SVR) in Part 2

Participants with SVR were defined as those with undetectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of treatment period Part 2

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With Sustained Virologic Response (SVR) in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants With Sustained Virologic Response (SVR) in Part 29
SecondaryNumber of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2

RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA between 4 weeks and 12 weeks after antiviral treatment.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
RVR6
eRVR5
SecondaryNumber of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2

EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 decrease in HCV RNA or undetectable HCV RNA) after 12 weeks of antiviral treatment. cEVR, a subset of EVR, is defined exclusively as undetectable HCV RNA after 12 weeks of antiviral treatment.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
EVR28
cEVR18
SecondaryNumber of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2

ETR is defined as undetectable HCV RNA at the end of Peg-IFN/RBV treatment.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 219
SecondaryMean Serum HCV RNA at the Indicated Time Points In Part 2

The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at Screening, Antiviral Baseline, Part 2 week 4, 12, 24, 36, 48 and at withdrawal.

Time frame:
Screening, Antviral baseline; Week 4, 12, 24, 36, 48, Withdrawal in Part 2
Reported as:
Mean · Log international unit per milliliter
Mean Serum HCV RNA at the Indicated Time Points In Part 2
Log international unit per milliliterEltrombopag + Antiviral Therapy: Part 2
Screening, n=416.41 ± 0.726
Antiviral Baseline, n=416.37 ± 0.767
Week 4, n=373.77 ± 1.741
Week 12, n=362.52 ± 1.734
Week 24, n=362.46 ± 1.876
Week 36, n=342.69 ± 2.177
Week 48, n=312.63 ± 2.275
Withdrawal, n=103.87 ± 2.275
SecondaryMean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2

The HCV is a small, enveloped, single-stranded, positive-sense RNA virus. Log-Transformed HCV RNA was assessed at FU Baseline, FU Week 12 and FU Week 24 during Follow-up Period after Part 2

Time frame:
FU Baseline, FU Week 12 and FU Week 24 after Part 2
Reported as:
Mean · Log international unit per milliliter
Mean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2
Log international unit per milliliterEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, n=343.10 ± 2.422
FU Week 12, n=345.04 ± 2.551
FU Week 24, n=314.82 ± 2.436
SecondaryNumber of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

Time frame:
From Baseline up to week 9 in Part 1
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1
ParticipantsEltrombopag Dose Escalation: Part 1
Any AE13
Any SAE0
Fatal AE0
Drug-related AE4
AE leading to withdrawal0
SAE leading to withdrawal0
On-going AE at the endo of study/withdrawal1
SecondaryNumber of Participants With Any AE and Any SAE in Part 2

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

Time frame:
From Antiviral Baseline up to Week 48 in Part 2
Reported as:
Number · Participants
Number of Participants With Any AE and Any SAE in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Any AE41
Any SAE3
Fatal AE0
Drug-related AE41
AE leading to withdrawal9
SAE leading to withdrawal3
On-going AE at the end of study/withdrawal34
SecondaryNumber of Participants With Any AE and Any SAE During Follow-up Period After Part 2

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

Time frame:
From FU Baseline up to FU Week 24 after Part 2
Reported as:
Number · Participants
Number of Participants With Any AE and Any SAE During Follow-up Period After Part 2
ParticipantsEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
Any AE25
Any SAE4
Fatal AE0
Drug-related AE6
AE leading to withdrawal0
SAE leading to withdrawal0
On-going AE at the end of study/withdrawal16
SecondaryMean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period

Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

Time frame:
Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, and FU Week 24
Reported as:
Mean · Millimeter of mercury (mmHg)
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period
Millimeter of mercury (mmHg)Eltrombopag Dose Escalation: Part 1
SBP, Week 1, n=380.9 ± 9.86
SBP, Week 2, n=30-1.7 ± 12.42
SBP, Week 3, n=112.8 ± 11.07
SBP, Week 4, n=6-2.8 ± 9.79
SBP, Week 5, n=3-1.0 ± 9.54
SBP, Week 6, n=3-4.0 ± 3.00
SBP, Week 7, n=3-1.3 ± 5.69
SBP, Week 8, n=212.0 ± 15.56
SBP, Week 9, n=13.0 ± NA
SBP, Withdrawal, n=413.5 ± 13.96
SBP, Follow Up, week 4, n=3-1.0 ± 8.54
SBP, Follow Up, week 12, n=39.0 ± 8.89
SBP, Follow Up, week 24, n=32.7 ± 10.07
DBP, Week 1, n=38-0.5 ± 8.81
DBP, Week 2, n=30-2.1 ± 8.04
DBP, Week 3, n=11-1.6 ± 7.98
DBP, Week 4, n=6-1.7 ± 8.04
DBP, Week 5, n=3-7.3 ± 9.87
DBP, Week 6, n=3-3.3 ± 7.64
DBP, Week 7, n=3-9.0 ± 7.00
DBP, Week 8, n=26.0 ± 14.14
DBP, Week 9, n=1-10.0 ± NA
DBP, Withdrawal, n=45.8 ± 12.09
DBP, FU Week 4, n=30.3 ± 5.51
DBP, FU Week 12, n=34.0 ± 10.39
DBP, FU Week 24, n=3-0.3 ± 1.53
SecondaryMean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2

Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

Time frame:
Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2
mmHgEltrombopag + Antiviral Therapy: Part 2
SBP, Antiviral Baseline, n=400.2 ± 13.99
SBP, Week 1, n=40-5.9 ± 10.37
SBP, Week 2, n=40-8.7 ± 13.35
SBP, Week 4, n=37-5.2 ± 13.69
SBP, Week 6, n=36-3.9 ± 13.09
SBP, Week 8, n=36-6.0 ± 14.53
SBP, Week 12, n=36-5.7 ± 13.08
SBP, Week 16, n=36-5.5 ± 16.52
SBP, Week 20, n=36-4.4 ± 15.18
SBP, Week 24, n=36-2.1 ± 15.70
SBP, Week 28, n=34-6.3 ± 15.76
SBP, Week 32, n=34-5.2 ± 17.60
SBP, Week 36, n=34-5.6 ± 15.36
SBP, Week 40, n=33-5.1 ± 13.47
SBP, Week 44, n=31-4.6 ± 16.60
SBP, Week 48, n=31-2.9 ± 12.37
SBP, withdrawal, n=100.5 ± 17.26
DBP, Antiviral Baseline, n=40-0.4 ± 6.35
DBP, Week 1, n=40-3.5 ± 9.28
DBP, Week 2, n=40-4.0 ± 9.59
DBP, Week 4, n=37-3.5 ± 9.81
DBP, Week 6, n=36-3.9 ± 9.16
DBP, Week 8, n=36-6.0 ± 9.62
DBP, Week 12, n=36-5.9 ± 10.07
DBP, Week 16, n=36-4.7 ± 9.94
DBP, Week 20, n=36-5.7 ± 11.17
DBP, Week 24, n=36-4.5 ± 12.34
DBP, Week 28, n=34-7.9 ± 11.48
DBP, Week 32, n=34-7.1 ± 11.97
DBP, Week 36, n=34-5.4 ± 9.96
DBP, Week 40, n=33-6.8 ± 9.69
DBP, Week 44, n=31-5.8 ± 12.18
DBP, Week 48, n=31-3.8 ± 8.36
DBP, withdrawal, n=10-2.4 ± 8.24
SecondaryMean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2

Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed.

Time frame:
FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Reported as:
Mean · mmHg
Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2
mmHgEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
SBP, FU Baseline, n=40126.5 ± 11.30
SBP, FU Week 4, n=40125.4 ± 11.74
SBP, Week 12, n=40126.7 ± 10.86
SBP, Week 24, n=37128.4 ± 12.68
DBP, FU Baseline, n=4073.8 ± 8.85
DBP, FU Week 4, n=4074.3 ± 8.91
DBP, FU Week 12, n=4076.2 ± 9.40
DBP, FU Week 24, n=3775.7 ± 9.48
SecondaryMean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period

The heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Reported as:
Mean · Beats per minute (bpm)
Mean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period
Beats per minute (bpm)Eltrombopag Dose Escalation: Part 1
Week 1, n=380.1 ± 7.07
Week 2, n=30-0.1 ± 7.42
Week 3, n=110.1 ± 4.50
Week 4, n=62.8 ± 4.07
Week 5, n=30.3 ± 7.37
Week 6, n=32.0 ± 5.29
Week 7, n=33.0 ± 7.00
Week 8, n=2-1.0 ± 5.66
Week 9, n=1-4.0 ± NA
Withdrawal, n=42.8 ± 8.30
FU Week 4, n=30.7 ± 12.66
FU Week 12, n=33.7 ± 9.07
FU Week 24, n=32.0 ± 9.54
SecondaryMean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2

The heart rate was measured in participants at the indicated time points. Mean change from Antiviral Baseline was calculated as the value at the indicated time points minus the value at Antiviral Baseline.

Time frame:
Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Reported as:
Mean · bpm
Mean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2
bpmEltrombopag + Antiviral Therapy: Part 2
Antiviral Baseline, n=400.4 ± 7.56
Week 1, n=40-3.5 ± 9.51
Week 2, n=401.0 ± 9.57
Week 4, n=373.9 ± 9.29
Week 6, n=365.9 ± 9.78
Week 8, n=364.7 ± 10.60
Week 12, n=365.8 ± 10.34
Week 16, n=366.2 ± 9.91
Week 20, n=364.5 ± 10.54
Week 24, n=364.5 ± 9.79
Week 28, n=345.6 ± 9.85
Week 32, n=343.6 ± 8.80
Week 36, n=344.7 ± 9.07
Week 40, n=335.2 ± 8.20
Week 44, n=315.2 ± 7.11
Week 48, n=313.6 ± 7.18
Withdrawal, n=105.1 ± 11.86
SecondaryMean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2

The heart rate was measured in participants at the indicated time points.

Time frame:
FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Reported as:
Mean · bpm
Mean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2
bpmEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, n=4078.3 ± 8.77
FU Week 4, n=4079.5 ± 9.38
FU Week 12, n=4074.0 ± 8.64
FU Week 24, n=3774.6 ± 9.58
SecondaryMean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period

The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Reported as:
Mean · Kilogram (kg)
Mean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period
Kilogram (kg)Eltrombopag Dose Escalation: Part 1
Week 1, n=380.09 ± 0.807
Week 2, n=300.05 ± 1.239
Week 3, n=110.75 ± 1.196
Week 4, n=61.15 ± 0.931
Week 5, n=31.00 ± 1.400
Week 6, n=31.03 ± 0.723
Week 7, n=30.57 ± 1.159
Week 8, n=20.15 ± 1.909
Week 9, n=10.20 ± NA
Withdrawal, n=40.30 ± 1.519
FU Week 4, n=30.90 ± 1.212
FU Week 12, n=30.93 ± 3.009
FU Week 24, n=31.17 ± 2.894
SecondaryMean Change From Baseline in Weight at the Indicated Time Points in Part 2

The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline; Antiviral Baseline, Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Reported as:
Mean · kg
Mean Change From Baseline in Weight at the Indicated Time Points in Part 2
kgEltrombopag + Antiviral Therapy: Part 2
Antivital Baseline, n=400.04 ± 1.336
Week 1, n=40-0.95 ± 1.131
Week 2, n=40-1.14 ± 1.314
Week 4, n=37-1.04 ± 1.060
Week 6, n=36-1.05 ± 1.344
Week 8, n=36-1.28 ± 1.581
Week 12, n=36-1.73 ± 1.887
Week 16, n=36-2.13 ± 2.175
Week 20, n=36-2.49 ± 2.265
Week 24, n=36-3.11 ± 2.488
Week 28, n=34-3.00 ± 3.104
Week 32, n=34-3.16 ± 3.100
Week 36, n=34-3.43 ± 3.188
Week 40, n=33-3.61 ± 3.000
Week 44, n=31-3.39 ± 3.018
Week 48, n=31-3.76 ± 2.950
Withdrawal, n=10-3.04 ± 3.584
SecondaryMean Weight at the Indicated Time Points During Follow-up Period After Part 2

The weight of participants was recorded at the indicated time points.

Time frame:
FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Reported as:
Mean · kg
Mean Weight at the Indicated Time Points During Follow-up Period After Part 2
kgEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, n=4055.77 ± 11.403
FU Week 4, n=4056.37 ± 11.627
FU Week 12, n=4057.05 ± 11.841
FU Week 24, n=3757.84 ± 12.478
SecondaryMean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period

The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Reported as:
Mean · Degrees centigrade
Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period
Degrees centigradeEltrombopag Dose Escalation: Part 1
Week 1, n=38-0.04 ± 0.439
Week 2, n=300.03 ± 0.445
Week 3, n=110.06 ± 0.284
Week 4, n=60.07 ± 0.367
Week 5, n=3-0.07 ± 0.153
Week 6, n=3-0.10 ± 0.173
Week 7, n=3-0.40 ± 0.100
Week 8, n=2-0.50 ± 0.141
Week 9, n=1-1.10 ± NA
Withdrawal, n=4-0.18 ± 0.171
FU Week 4, n=30.07 ± 0.153
FU Week 12, n=3-0.23 ± 0.493
FU Week 24, n=3-0.17 ± 0.306
SecondaryMean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2

The Body temperature of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

Time frame:
Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Reported as:
Mean · Degrees centigrade
Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2
Degrees centigradeEltrombopag + Antiviral Therapy: Part 2
Antiviral Baseline, n=410.08 ± 0.662
Week 1, n=400.09 ± 0.398
Week 2, n=400.17 ± 0.459
Week 4, n=370.16 ± 0.439
Week 6, n=360.19 ± 0.499
Week 8, n=360.22 ± 0.426
Week 12, n=360.28 ± 0.440
Week 16, n=360.22 ± 0.392
Week 20, n=360.20 ± 0.386
Week 24, n=360.26 ± 0.422
Week 28, n=340.27 ± 0.424
Week 32, n=340.21 ± 0.435
Week 36, n=340.22 ± 0.462
Week 40, n=330.26 ± 0.374
Week 44, n=310.20 ± 0.492
Week 48, n=310.15 ± 0.498
Withdrawal, n=100.38 ± 0.724
SecondaryMean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2

The Body temperature of participants was recorded at the indicated time points..

Time frame:
FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Reported as:
Mean · Degrees centigrade
Mean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2
Degrees centigradeEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, n=4036.44 ± 0.417
FU Week 4, n=4036.37 ± 0.360
FU Week 12, n=4036.29 ± 0.350
FU Week 24, n=3736.90 ± 0.377
SecondaryMean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc

The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

Time frame:
Baseline; Week 1, 2, 3, 4, 5, 6, 7, 8, 9, Withdrawal in Part 1 and FU Week 4, FU Week 12, FU Week 24
Reported as:
Mean · kilogram per meters squared (kg/m^2)
Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc
kilogram per meters squared (kg/m^2)Eltrombopag Dose Escalation: Part 1
Week 1, n=380.03 ± 0.302
Week 2, n=300.02 ± 0.457
Week 3, n=110.26 ± 0.415
Week 4, n=60.39 ± 0.325
Week 5, n=30.36 ± 0.504
Week 6, n=30.36 ± 0.248
Week 7, n=30.20 ± 0.417
Week 8, n=20.04 ± 0.704
Week 9, n=10.08 ± NA
Withdrawal, n=40.09 ± 0.572
FU, Week 4, n=30.34 ± 0.432
FU, Week 12, n=30.36 ± 1.084
FU, Week 24, n=30.41 ± 1.042
SecondaryMean Change From Baseline in BMI at the Indicated Time Points in Part 2

The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline

Time frame:
Baseline; Antiviral Baseline,Week 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal in Part 2
Reported as:
Mean · kg/m^2
Mean Change From Baseline in BMI at the Indicated Time Points in Part 2
kg/m^2Eltrombopag + Antiviral Therapy: Part 2
Antiviral Baseline, n=400.01 ± 0.476
Week 1, n=40-0.37 ± 0.408
Week 2, n=40-0.44 ± 0.495
Week 4, n=37-0.41 ± 0.424
Week 6, n=36-0.42 ± 0.534
Week 8, n=36-0.51 ± 0.624
Week 12, n=36-0.70 ± 0.723
Week 16, n=36-0.86 ± 0.844
Week 20, n=36-1.01 ± 0.891
Week 24, n=36-1.25 ± 0.965
Week 28, n=34-1.21 ± 1.212
Week 32, n=34-1.28 ± 1.228
Week 36, n=34-1.38 ± 1.264
Week 40, n=33-1.45 ± 1.200
Week 44, n=31-1.36 ± 1.174
Week 48, n=31-1.50 ± 1.146
Withdrawal, n=10-1.23 ± 1.529
SecondaryMean BMI at the Indicated Time Points During Follow-up Period After Part 2

The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.

Time frame:
FU Baseline, FU Week 4, FU Week 12 and FU Week 24 after Part 2
Reported as:
Mean · kilogram per meters squared (kg/m^2)
Mean BMI at the Indicated Time Points During Follow-up Period After Part 2
kilogram per meters squared (kg/m^2)Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, n=4021.89 ± 3.486
FU Week 4, n=4022.11 ± 3.474
FU Week 12, n=4022.37 ± 3.531
FU Week 24, n=3722.54 ± 3.521
SecondaryNumber of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1

Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 1. Clinical chemistry parameters included albumin, alkaline phosphatase (ALP), ALT, aspartate amino transferase (AST), total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From Baseline up to Week 9
Reported as:
Number · Participants
Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1
ParticipantsEltrombopag Dose Escalation: Part 1
Albumin: Any Grade Increase5
Albumin: Increase to G15
Albumin: Increase to G20
Albumin: Increase to G30
Albumin: Increase to G40
ALP: Any Grade Increase4
ALP: Increase to G12
ALP: Increase to G22
ALP: Increase to G30
ALP: Increase to G40
ALT: Any Grade Increase5
ALT: Increase to G11
ALT: Increase to G22
ALT: Increase to G32
ALT: Increase to G40
AST:Any Grade Increase9
AST:Increase to G12
AST:Increase to G25
AST:Increase to G32
AST:Increase to G40
Total Bilirubin:Any Grade Increase8
Total Bilirubin:Increase to G16
Total Bilirubin:Increase to G22
Total Bilirubin:Increase to G30
Total Bilirubin:Increase to G40
Calcium:Any Grade Increase5
Calcium:Increase to G15
Calcium:Increase to G20
Calcium:Increase to G30
Calcium:Increase to G40
Creatinine:Any Grade Increase1
Creatinine:Increase to G11
Creatinine:Increase to G20
Creatinine:Increase to G30
Creatinine:Increase to G40
Potassium:Any Grade Increase3
Potassium:Increase to G13
Potassium:Increase to G20
Potassium:Increase to G30
Potassium:Increase to G40
Sodium:Any Grade Increase2
Sodium:Increase to G12
Sodium:Increase to G20
Sodium:Increase to G30
Sodium:Increase to G40
Uric Acid:Any Grade Increase6
Uric acid:Increase to G15
Uric acid:Increase to G21
Uric acid:Increase to G30
Uric acid:Increase to G40
SecondaryNumber of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2

Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From Antiviral Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Albumin:Any Grade Increase18
Albumin:Increase to G115
Albumin:Increase to G23
Albumin:Increase to G30
Albumin:Increase to G40
ALP:Any Grade Increase3
ALP:Increase to G13
ALP:Increase to G20
ALP:Increase to G30
ALP:Increase to G40
ALT:Any Grade Increase14
ALT:Increase to G11
ALT:Increase to G26
ALT:Increase to G36
ALT:Increase to G41
AST:Any Grade Increase22
AST:Increase to G14
AST:Increase to G211
AST:Increase to G36
AST:Increase to G41
Total Bilirubin:Any Grade Increase20
Total Bilirubin:Increase to G17
Total Bilirubin:Increase to G29
Total Bilirubin:Increase to G33
Total Bilirubin:Increase to G41
Calcium:Any Grade Increase31
Calcium:Increase to G125
Calcium:Increase to G26
Calcium:Increase to G30
Calcium:Increase to G40
Creatinine:Any Grade Increase3
Creatinine:Increase to G12
Creatinine:Increase to G21
Creatinine:Increase to G30
Creatinine:Increase to G40
Potassium:Any Grade Increase8
Potassium:Increase to G18
Potassium:Increase to G20
Potassium:Increase to G30
Potassium:Increase to G40
Sodium:Any Grade Increase7
Sodium:Increase to G17
Sodium:Increase to G20
Sodium:Increase to G30
Sodium:Increase to G40
Uric acid:Any Grade Increase13
Uric acid:Increase to G19
Uric acid:Increase to G24
Uric acid:Increase to G30
Uric acid:Increase to G40
SecondaryNumber of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2

Blood samples for the assessment of clinical chemistry parameters were taken at intervals in Part 2. Clinical chemistry parameters included albumin, ALP, ALT, AST, total bilirubin, calcium, creatinine, potassium, sodium, and uric acid. Per DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 0=none, 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From FU Week 4 to FU Week 24
Reported as:
Number · Participants
Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2
ParticipantsEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
Albumin:Any Grade Increase3
Albumin:Increase to G12
Albumin:Increase to G21
Albumin:Increase to G30
Albumin:Increase to G40
ALP:Any Grade Increase5
ALP:Increase to G14
ALP:Increase to G21
ALP:Increase to G30
ALP:Increase to G40
ALT:Any Grade Increase9
ALT:Increase to G14
ALT:Increase to G24
ALT:Increase to G30
ALT:Increase to G41
AST:Any Grade Increase10
AST:Increase to G13
AST:Increase to G26
AST:Increase to G30
AST:Increase to G41
Total Bilirubin:Any Grade Increase4
Total Bilirubin:Increase to G12
Total Bilirubin:Increase to G22
Total Bilirubin:Increase to G30
Total Bilirubin:Increase to G40
Calcium:Any Grade Increase2
Calcium:Increase to G12
Calcium:Increase to G20
Calcium:Increase to G30
Calcium:Increase to G40
Calcium serum high: Any Grade Increase0
Calcium, serum high: Increase to G10
Calcium, serum high: Increase to G20
Calcium, serum high: Increase to G30
Calcium, serum high: Increase to G40
Calcium serum low: Any Grade Increase2
Calcium, serum low: Increase to G12
Calcium, serum low: Increase to G20
Calcium, serum low: Increase to G30
Calcium, serum low: Increase to G40
Creatinine: Any Grade Increase1
Creatinine: Increase to G11
Creatinine: Increase to G20
Creatinine: Increase to G30
Creatinine: Increase to G40
Potassium:Any Grade Increase3
Potassium:Increase to G13
Potassium:Increase to G20
Potassium:Increase to G30
Potassium:Increase to G40
Potassium, serum high:Any Grade Increase0
Potassium, serum high:Increase to G10
Potassium, serum high:Increase to G20
Potassium, serum high:Increase to G30
Potassium, serum high:Increase to G40
Potassium, serum low:Any Grade Increase3
Potassium, serum low:Increase to G13
Potassium, serum low:Increase to G20
Potassium, serum low:Increase to G30
Potassium, serum low:Increase to G40
Sodium:Any Grade Increase1
Sodium:Increase to G11
Sodium:Increase to G20
Sodium:Increase to G30
Sodium:Increase to G40
Sodium, serum high:Any Grade Increase1
Sodium, serum high:Increase to G11
Sodium, serum high:Increase to G20
Sodium, serum high:Increase to G30
Sodium, serum high:Increase to G40
Sodium, serum low:Any Grade Increase0
Sodium, serum low:Increase to G10
Sodium, serum low:Increase to G20
Sodium, serum low:Increase to G30
Sodium, serum low:Increase to G40
Uric acid:Any Grade Increase2
Uric acid:Increase to G12
Uric acid:Increase to G20
Uric acid:Increase to G30
Uric acid:Increase to G40
SecondaryNumber of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1

Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 1 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From Baseline up to Week 9
Reported as:
Number · Participants
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1
ParticipantsEltrombopag Dose Escalation: Part 1
Hemoglobin:Any Grade Increase1
Hemoglobin:Increase to G11
Hemoglobin:Increase to G20
Hemoglobin:Increase to G30
Hemoglobin:Increase to G40
Lymphocytes:Any Grade Increase4
Lymphocytes:Increase to G11
Lymphocytes:Increase to G20
Lymphocytes:Increase to G33
Lymphocytes:Increase to G40
Total Neutrophils:Any Grade Increase8
Total Neutrophils:Increase to G16
Total Neutrophils:Increase to G22
Total Neutrophils:Increase to G30
Total Neutrophils:Increase to G40
Platelet count:Any Grade Increase0
Platelet count:Increase to G10
Platelet count:Increase to G20
Platelet count:Increase to G30
Platelet count:Increase to G40
White Blood Cell count:Any Grade Increase7
White Blood Cell count:Increase to G17
White Blood Cell count:Increase to G20
White Blood Cell count:Increase to G30
White Blood Cell count:Increase to G40
SecondaryNumber of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2

Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From Antiviral Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Hemoglobin:Any Grade Increase38
Hemoglobin:Increase to G13
Hemoglobin:Increase to G211
Hemoglobin:Increase to G324
Hemoglobin:Increase to G40
Lymphocytes:Any Grade Increase26
Lymphocytes:Increase to G10
Lymphocytes:Increase to G26
Lymphocytes:Increase to G312
Lymphocytes:Increase to G48
Total Neutrophils:Any Grade Increase38
Total Neutrophils:Increase to G18
Total Neutrophils:Increase to G210
Total Neutrophils:Increase to G316
Total Neutrophils:Increase to G44
Platelet count:Any Grade Increase5
Platelet count:Increase to G10
Platelet count:Increase to G20
Platelet count:Increase to G35
Platelet count:Increase to G40
White Blood Cell count:Any Grade Increase38
White Blood Cell count:Increase to G110
White Blood Cell count:Increase to G218
White Blood Cell count:Increase to G39
White Blood Cell count:Increase to G41
SecondaryNumber of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2

Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL in Part 2 are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From FU Week 4 to FU Week 24
Reported as:
Number · Participants
Number of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2
ParticipantsEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
Hemoglobin:Any Grade Increase2
Hemoglobin:Increase to G12
Hemoglobin:Increase to G20
Hemoglobin:Increase to G30
Hemoglobin:Increase to G40
Lymphocytes:Any Grade Increase2
Lymphocytes:Increase to G10
Lymphocytes:Increase to G22
Lymphocytes:Increase to G30
Lymphocytes:Increase to G40
Total Neutrophils:Any Grade Increase7
Total Neutrophils:Increase to G13
Total Neutrophils:Increase to G24
Total Neutrophils:Increase to G30
Total Neutrophils:Increase to G40
Platelet count:Any Grade Increase15
Platelet count:Increase to G10
Platelet count:Increase to G28
Platelet count:Increase to G37
Platelet count:Increase to G40
White Blood Cell count:Any Grade Increase6
White Blood Cell count:Increase to G13
White Blood Cell count:Increase to G23
White Blood Cell count:Increase to G30
White Blood Cell count:Increase to G40
SecondaryNumber of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period

Urinalysis parameters included: urine bilirubin (UB), urine occult blood (UOB), urine glucose (UG), urine ketones (UK), pH, urine protein (UP), urine specific gravity (USG) and urine urobilinogen (UU). The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as 1+, (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.

Time frame:
Screening, Baseline, Week 1, 2, 3, 4, 7, 8, Withdrawal, FU Week 24
Reported as:
Number · Participants
Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period
ParticipantsEltrombopag Dose Escalation: Part 1
Screening, UB, (-), n=456
Screening, UB, Neg., n=4539
Screening, UOB, 1+, n=454
Screening, UOB, 2+, n=451
Screening, UOB, 3+, n=451
Screening, UOB, (-), n=456
Screening, UOB, Neg., n=4531
Screening, UOB, trace., n=452
Screening, UG, (-), n=457
Screening, UG, 0.5, n=451
Screening, UG, Neg., n=4537
Screening, UK, (-), n=457
Screening, UK, Neg., n=4538
Screening, pH, 5, n=451
Screening, pH, 5.5, n=459
Screening, pH, 6, n=459
Screening, pH, 6.5, n=4512
Screening, pH, 7, n=459
Screening, pH, 7.5, n=455
Screening, UP, 1+., n=451
Screening, UP, (-), n=455
Screening, UP, Neg., n=4535
Screening, UP, trace, n=454
Screening, UU, 1+, n=452
Screening, UU, (-), n=451
Screening, UU, 0.1, n=455
Screening, UU, 1, n=456
Screening, UU, 2, n=454
Screening, UU, trace, n=4519
Screening, UU, normal, n=458
Screening, USG, 1.005, n=452
Screening, USG, 1.006, n=451
Screening, USG, 1.007, n=452
Screening, USG, 1.008, n=451
Screening, USG, 1.009, n=451
Screening, USG, 1.01, n=453
Screening, USG, 1.011, n=452
Screening, USG, 1.012, n=451
Screening, USG, 1.013, n=451
Screening, USG, 1.014, n=454
Screening, USG, 1.015, n=454
Screening, USG, 1.017, n=452
Screening, USG, 1.018, n=454
Screening, USG, 1.019, n=451
Screening, USG, 1.02, n=458
Screening, USG, 1.021, n=451
Screening, USG, 1.022, n=451
Screening, USG, 1.024, n=451
Screening, USG, 1.025, n=451
Screening, USG, 1.026, n=453
Screening, USG, 1.03, n=451
Baseline, UB, (-), n=456
Baseline, UB, Neg., n=4539
Baseline, UOB, 1+, n=451
Baseline, UOB, 2+, n=451
Baseline, UOB, 3+, n=452
Baseline, UOB, (-), n=456
Baseline, UOB, Neg., n=4532
Baseline, UOB, trace., n=453
Baseline, UG, 2+, n=451
Baseline, UG, (-), n=457
Baseline, UG, 0.1, n=451
Baseline, UG, 0.5, n=451
Baseline, UG, Neg., n=4535
Baseline, UK, (-), n=457
Baseline, UK, Neg., n=4538
Baseline, pH, 5, n=452
Baseline, pH, 5.5, n=458
Baseline, pH, 6, n=4513
Baseline, pH, 6.5, n=4511
Baseline, pH, 7, n=457
Baseline, pH, 7.5, n=453
Baseline, pH, 8, n=451
Baseline, UP, 1+., n=451
Baseline, UP, (-), n=455
Baseline, UP, Neg., n=4536
Baseline, UP, trace, n=453
Baseline, UU, 1+, n=457
Baseline, UU, (-), n=451
Baseline, UU, 0.1, n=454
Baseline, UU, 1, n=4510
Baseline, UU, 2, n=451
Baseline, UU, trace, n=4515
Baseline, UU, normal, n=457
Baseline, USG, 1.003, n=451
Baseline, USG, 1.005, n=453
Baseline, USG, 1.006, n=451
Baseline, USG, 1.007, n=451
Baseline, USG, 1.009, n=451
Baseline, USG, 1.01, n=456
Baseline, USG, 1.011, n=452
Baseline, USG, 1.012, n=451
Baseline, USG, 1.013, n=452
Baseline, USG, 1.014, n=451
Baseline, USG, 1.015, n=452
Baseline, USG, 1.016, n=452
Baseline, USG, 1.017, n=451
Baseline, USG, 1.018, n=453
Baseline, USG, 1.019, n=452
Baseline, USG, 1.02, n=455
Baseline, USG, 1.021, n=453
Baseline, USG, 1.022, n=451
Baseline, USG, 1.023, n=451
Baseline, USG, 1.025, n=453
Baseline, USG, 1.028, n=452
Baseline, USG, 1.03, n=451
Week 1, UB, Neg, n=11
Week 1, UOB, Neg, n=11
Week 1, UG, Neg, n=11
Week 1, UK, Neg, n=11
Week 1, pH, 7.5, n=11
Week 1, UP, trace, n=11
Week 1, USG, 1.021, n=11
Week 1, UU, trace, n=11
Week 2, UB, Neg, n=33
Week 2, UOB, Neg, n=33
Week 2, UG, 0.25, n=31
Week 2, UG, Neg, n=32
Week 2, UK, Neg, n=33
Week 2, pH, 6, n=31
Week 2, pH, 6.5, n=32
Week 2, UP, Neg, n=33
Week 2, USG, 1.016, Neg, n=31
Week 2, USG, 1.019, n=31
Week 2, USG, 1.02, n=31
Week 2, UU, 0.1, n=31
Week 2, UU, trace, n=31
Week 2, UU, normal, n=31
Week 3, UB, Neg, n=22
Week 3, UOB, Neg, n=22
Week 3, UG, >=1.0, n=21
Week 3, UG, Neg, n=21
Week 3, UK, Neg, n=22
Week 3, pH, 6, n=21
Week 3, pH, 6.5, n=21
Week 3, UP, Neg, n=22
Week 3, USG, 1.015, n=21
Week 3, USG, 1.02, n=21
Week 3, UU, 0.1, n=21
Week 3, UU, 4, n=21
Week 4, UB, Neg, n=55
Week 4, UOB, Neg, n=55
Week 4, UG, >=1.0, n=51
Week 4, UG, Neg, n=54
Week 4, UK, Neg, n=55
Week 4, pH, 5.5, n=51
Week 4, pH, 6, n=52
Week 4, pH, 6.5, n=52
Week 4, UP, Neg, n=55
Week 4, USG, 1.015, n=51
Week 4, USG, 1.02, n=52
Week 4, USG, 1.025, n=51
Week 4, USG, 1.026, n=51
Week 4, UU, 1, n=52
Week 4, UU, 2, n=51
Week 4, UU, trace, n=52
Week 7, UB, Neg, n=11
Week 7, UOB, Neg, n=11
Week 7, UG, 0.5, n=11
Week 7, UK, Neg, n=11
Week 7, pH, 7, n=11
Week 7, UP, Neg, n=11
Week 7, USG, 1.02, n=11
Week 7, UU, 2, n=11
Week 8, UB, Neg, n=22
Week 8, UOB, Neg, n=21
Week 8, UOB, trace, n=21
Week 8, UG, 0.1 n=21
Week 8, UG, Neg, n=21
Week 8, UK, Neg, n=22
Week 8, pH, 6, n=22
Week 8, UP, Neg, n=22
Week 8, USG, 1.023, n=21
Week 8, USG, 1.025, n=21
Week 8, UU, 0.1, n=21
Week 8, UU, trace, n=21
Withdrawal, UB, Neg, n=44
Withdrawal, UOB, Neg, n=44
Withdrawal, UG, 0.5, n=41
Withdrawal, UG, Neg, n=43
Withdrawal, UK, Neg, n=44
Withdrawal, pH, 6, n=42
Withdrawal, pH, 6.5, n=41
Withdrawal, pH, 8, n=41
Withdrawal, UP, Neg, n=44
Withdrawal, USG, 1.008, n=41
Withdrawal, USG, 1.01, n=41
Withdrawal, USG, 1.018, n=41
Withdrawal, USG, 1.025, n=41
Withdrawal, UU, 1+, n=42
Withdrawal, UU, 0.1, n=41
Withdrawal, UU, 1, n=41
FU, Week 24, UB, Neg, n=33
FU Week 24, UOB, 1+, n=31
FU Week 24, UOB, Neg, n=32
FU Week 24, UG, Neg, n=33
FU Week 24, UK, Neg, n=33
FU Week 24, pH, 5.5, n=31
FU Week 24, pH, 6, n=31
FU Week 24, pH, 7, n=31
FU Week 24, UP, Neg, n=33
FU Week 24, USG, 1.004, n=31
FU Week 24, USG, 1.01, n=31
FU Week 24, USG, 1.02, n=31
FU Week 24, UU, 0.1, n=31
FU Week 24, UU, 1, n=31
FU Week 24, UU, trace, n=31
SecondaryNumber of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2

Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.

Time frame:
Antiviral Baseline,Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, Withdrawal
Reported as:
Number · Participants
Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2
ParticipantsEltrombopag + Antiviral Therapy: Part 2
Antiviral Baseline, UB, (-), n=415
Antiviral Baseline, UB, Neg., n=4136
Antiviral Baseline, UOB, 1+, n=411
Antiviral Baseline, UOB, (-), n=415
Antiviral Baseline, UOB, Neg., n=4133
Antiviral Baseline, UOB, trace., n=412
Antiviral Baseline, UG, 1+, n=411
Antiviral Baseline, UG, 2+, n=411
Antiviral Baseline, UG, (-), n=415
Antiviral Baseline, UG, 0.25, n=411
Antiviral Baseline, UG, 0.5, n=411
Antiviral Baseline, UG, >=1.0, n=411
Antiviral Baseline, UG, Neg., n=4131
Antiviral Baseline, UK, (-), n=415
Antiviral Baseline, UK, Neg., n=4135
Antiviral Baseline, UK, trace, n=411
Antiviral Baseline, pH, 5, n=411
Antiviral Baseline, pH, 5.5, n=416
Antiviral Baseline, pH, 6, n=4111
Antiviral Baseline, pH, 6.5, n=4112
Antiviral Baseline, pH, 7, n=416
Antiviral Baseline, pH, 7.5, n=414
Antiviral Baseline, pH, 8.5, n=411
Antiviral Baseline, UP, (-), n=415
Antiviral Baseline, UP, Neg, n=4134
Antiviral Baseline, UP, trace, n=412
Antiviral Baseline, USG, 1.005, n=411
Antiviral Baseline, USG, 1.006, n=411
Antiviral Baseline, USG, 1.01, n=413
Antiviral Baseline, USG, 1.011, n=414
Antiviral Baseline, USG, 1.012, n=412
Antiviral Baseline, USG, 1.013, n=412
Antiviral Baseline, USG, 1.014, n=412
Antiviral Baseline, USG, 1.015, n=414
Antiviral Baseline, USG, 1.016, n=413
Antiviral Baseline, USG, 1.017, n=411
Antiviral Baseline, USG, 1.018, n=412
Antiviral Baseline, USG, 1.019, n=411
Antiviral Baseline, USG, 1.02, n=418
Antiviral Baseline, USG, 1.021, n=411
Antiviral Baseline, USG, 1.022, n=411
Antiviral Baseline, USG, 1.023, n=411
Antiviral Baseline, USG, 1.024, n=411
Antiviral Baseline, USG, 1.025, n=411
Antiviral Baseline, USG, 1.026, n=411
Antiviral Baseline, USG, 1.027, n=411
Antiviral Baseline, UU, 1+, n=413
Antiviral Baseline, UU, 0.1, n=413
Antiviral Baseline, UU, 1, n=416
Antiviral Baseline, UU, 2, n=412
Antiviral Baseline, UU, 4, n=412
Antiviral Baseline, UU, Neg, n=411
Antiviral Baseline, UU, trace, n=4116
Antiviral Baseline, UU, normal, n=418
Week 4, UB, (-), n=376
Week 4, UB, Neg, n=3731
Week 4, UOB, 2+, n=371
Week 4, UOB, (-), n=376
Week 4, UOB, Neg, n=3730
Week 4, UG, (-), n=376
Week 4, UG, 0.1, n=371
Week 4, UG, Neg, n=3730
Week 4, UK, (-), n=376
Week 4, UK, Neg, n=3731
Week 4, pH, 5, n=371
Week 4, pH, 5.5, n=374
Week 4, pH, 6, n=379
Week 4, pH, 6.5, n=3712
Week 4, pH, 7, n=376
Week 4, pH, 7.5, n=374
Week 4, pH, 8, n=371
Week 4, UP, (-), n=374
Week 4, UP, Neg, n=3728
Week 4, UP, trace, n=375
Week 4, USG, 1.004, n=371
Week 4, USG, 1.005, n=373
Week 4, USG, 1.006, n=373
Week 4, USG, 1.008, n=371
Week 4, USG, 1.01, n=372
Week 4, USG, 1.011, n=372
Week 4, USG, 1.012, n=371
Week 4, USG, 1.013, n=372
Week 4, USG, 1.014, n=371
Week 4, USG, 1.015, n=374
Week 4, USG, 1.016, n=371
Week 4, USG, 1.017, n=372
Week 4, USG, 1.019, n=371
Week 4, USG, 1.02, n=376
Week 4, USG, 1.021, n=372
Week 4, USG, 1.022, n=372
Week 4, USG, 1.025, n=373
Week 4, UU, 1+, n=373
Week 4, UU, 0.1, n=372
Week 4, UU, 1, n=377
Week 4, UU, 2, n=372
Week 4, UU, 4, n=371
Week 4, UU, 8, n=371
Week 4, UU, Neg, n=372
Week 4, UU, trace, n=3715
Week 4, UU, normal, n=374
Week 8, UB, (-), n=364
Week 8, UB, 2, n=361
Week 8, UB, Neg, n=3631
Week 8, UOB, 1+, n=361
Week 8, UOB, 2+, n=361
Week 8, UOB, (-), n=364
Week 8, UOB, Neg, n=3630
Week 8, UG, 1+, n=361
Week 8, UG, (-), n=365
Week 8, UG, >=1.0, n=361
Week 8, UG, Neg, n=3629
Week 8, UK, (-), n=365
Week 8, UK, Neg, n=3630
Week 8, UK, trace, n=361
Week 8, pH, 5, n=361
Week 8, pH, 5.5, n=364
Week 8, pH, 6, n=367
Week 8, pH, 6.5, n=3613
Week 8, pH, 7, n=367
Week 8, pH, 7.5, n=363
Week 8, pH, 8, n=361
Week 8, UP, 1+, n=362
Week 8, UP, (-), n=362
Week 8, UP, Neg, n=3630
Week 8, UP, trace, n=362
Week 8, USG, 1.001, n=361
Week 8, USG, 1.003, n=361
Week 8, USG, 1.004, n=361
Week 8, USG, 1.005, n=362
Week 8, USG, 1.008, n=364
Week 8, USG, 1.01, n=363
Week 8, USG, 1.012, n=361
Week 8, USG, 1.013, n=363
Week 8, USG, 1.014, n=361
Week 8, USG, 1.015, n=362
Week 8, USG, 1.016, n=363
Week 8, USG, 1.018, n=363
Week 8, USG, 1.019, n=361
Week 8, USG, 1.02, n=362
Week 8, USG, 1.023, n=362
Week 8, USG, 1.025, n=364
Week 8, USG, <=1.005, n=361
Week 8, USG, >=1.030, n=361
Week 8, UU, 1+, n=365
Week 8, UU, (-), n=361
Week 8, UU, 0.1, n=362
Week 8, UU, 1, n=367
Week 8, UU, 2, n=361
Week 8, UU, 4, n=363
Week 8, UU, Neg, n=361
Week 8, UU, trace, n=3611
Week 8, UU, normal, n=365
Week 12, UB, (-), n=365
Week 12, UB, Neg, n=3631
Week 12, UOB, (-), n=365
Week 12, UOB, Neg, n=3631
Week 12, UG, (-), n=365
Week 12, UG, 0.25, n=361
Week 12, UG, Neg, n=3630
Week 12, UK, (-), n=365
Week 12, UK, 0, n=361
Week 12, UK, Neg, n=3630
Week 12, pH, 5, n=362
Week 12, pH, 5.5, n=362
Week 12, pH, 6, n=369
Week 12, pH, 6.5, n=3612
Week 12, pH, 7, n=367
Week 12, pH, 7.5, n=364
Week 12, UP, 1+, n=362
Week 12, UP, (-), n=363
Week 12, UP, Neg, n=3626
Week 12, UP, trace, n=365
Week 12, USG, 1.005, n=362
Week 12, USG, 1.006, n=363
Week 12, USG, 1.007, n=361
Week 12, USG, 1.008, n=361
Week 12, USG, 1.009, n=361
Week 12, USG, 1.01, n=361
Week 12, USG, 1.012, n=362
Week 12, USG, 1.014, n=362
Week 12, USG, 1.015, n=367
Week 12, USG, 1.016, n=361
Week 12, USG, 1.017, n=361
Week 12, USG, 1.018, n=362
Week 12, USG, 1.019, n=362
Week 12, USG, 1.02, n=365
Week 12, USG, 1.021, n=362
Week 12, USG, 1.022, n=362
Week 12, USG, 1.026, n=361
Week 12, UU, 1+, n=361
Week 12, UU, 0.1, n=363
Week 12, UU, 1, n=364
Week 12, UU, 2, n=363
Week 12, UU, 4, n=362
Week 12, UU, Neg, n=362
Week 12, UU, trace, n=3615
Week 12, UU, normal, n=366
Week 16, UB, (-), n=364
Week 16, UB, Neg, n=3632
Week 16, UOB, 1+, n=362
Week 16, UOB, 2+, n=362
Week 16, UOB, 3+, n=361
Week 16, UOB, (-), n=364
Week 16, UOB, Neg, n=3627
Week 16, UG, (-), n=364
Week 16, UG, 0.25, n=361
Week 16, UG, Neg, n=3631
Week 16, UK, (-), n=364
Week 16, UK, Neg, n=3631
Week 16, UK, trace, n=361
Week 16, pH, 5, n=361
Week 16, pH, 5.5, n=363
Week 16, pH, 6, n=3612
Week 16, pH, 6.5, n=369
Week 16, pH, 7, n=368
Week 16, pH, 7.5, n=363
Week 16, UP, 1+, n=361
Week 16, UP, (-), n=363
Week 16, UP, Neg, n=3630
Week 16, UP, trace, n=362
Week 16, USG, 1.005, n=362
Week 16, USG, 1.006, n=361
Week 16, USG, 1.007, n=361
Week 16, USG, 1.008, n=362
Week 16, USG, 1.009, n=361
Week 16, USG, 1.01, n=363
Week 16, USG, 1.014, n=361
Week 16, USG, 1.015, n=367
Week 16, USG, 1.016, n=362
Week 16, USG, 1.017, n=361
Week 16, USG, 1.018, n=362
Week 16, USG, 1.019, n=364
Week 16, USG, 1.02, n=363
Week 16, USG, 1.021, n=361
Week 16, USG, 1.022, n=362
Week 16, USG, 1.023, n=361
Week 16, USG, 1.025, n=361
Week 16, USG, 1.027, n=361
Week 16, UU, 1+, n=365
Week 16, UU, 2+, n=361
Week 16, UU, 0.1, n=363
Week 16, UU, 1, n=367
Week 16, UU, 4, n=362
Week 16, UU, Neg, n=363
Week 16, UU, trace, n=3611
Week 16, UU, normal, n=364
Week 20, UB, (-), n=362
Week 20, UB, Neg, n=3634
Week 20, UOB, 1+, n=361
Week 20, UOB, (-), n=362
Week 20, UOB, Neg, n=3633
Week 20, UG, (-), n=362
Week 20, UG, Neg, n=3633
Week 20, UG, trace, n=361
Week 20, UK, (-), n=362
Week 20, UK, Neg, n=3634
Week 20, pH, 5, n=364
Week 20, pH, 5.5, n=361
Week 20, pH, 6, n=3610
Week 20, pH, 6.5, n=368
Week 20, pH, 7, n=366
Week 20, pH, 7.5, n=367
Week 20, UP, 1+, n=362
Week 20, UP, (-), n=362
Week 20, UP, Neg, n=3630
Week 20, UP, trace, n=362
Week 20, USG, 1.004, n=361
Week 20, USG, 1.005, n=362
Week 20, USG, 1.006, n=361
Week 20, USG, 1.007, n=362
Week 20, USG, 1.009, n=363
Week 20, USG, 1.01, n=363
Week 20, USG, 1.013, n=363
Week 20, USG, 1.014, n=362
Week 20, USG, 1.015, n=362
Week 20, USG, 1.016, n=362
Week 20, USG, 1.017, n=362
Week 20, USG, 1.018, n=363
Week 20, USG, 1.019, n=361
Week 20, USG, 1.02, n=362
Week 20, USG, 1.021, n=362
Week 20, USG, 1.025, n=363
Week 20, USG, 1.029, n=361
Week 20, USG, <=1.005, n=361
Week 20, UU, 1+, n=363
Week 20, UU, 2+, n=361
Week 20, UU, 0.1, n=362
Week 20, UU, 1, n=367
Week 20, UU, 4, n=361
Week 20, UU, 8, n=362
Week 20, UU, Neg, n=362
Week 20, UU, trace, n=3613
Week 20, UU, normal, n=365
Week 24, UB, (-), n=362
Week 24, UB, Neg, n=3634
Week 24, UOB, 1+, n=362
Week 24, UOB, 3+, n=361
Week 24, UOB, (-), n=362
Week 24, UOB, Neg, n=3630
Week 24, UOB, trace, n=361
Week 24, UG, (-), n=362
Week 24, UG, 0.1, n=361
Week 24, UG, Neg, n=3633
Week 24, UK, (-), n=362
Week 24, UK, Neg, n=3633
Week 24, UK, trace, n=361
Week 24, pH, 5, n=362
Week 24, pH, 5.5, n=363
Week 24, pH, 6, n=369
Week 24, pH, 6.5, n=3612
Week 24, pH, 7, n=366
Week 24, pH, 7.5, n=363
Week 24, pH, 8.5, n=361
Week 24, UP, (-), n=362
Week 24, UP, Neg, n=3628
Week 24, UP, trace, n=366
Week 24, USG, 1.008, n=361
Week 24, USG, 1.009, n=363
Week 24, USG, 1.01, n=363
Week 24, USG, 1.011, n=364
Week 24, USG, 1.012, n=362
Week 24, USG, 1.013, n=361
Week 24, USG, 1.014, n=362
Week 24, USG, 1.015, n=367
Week 24, USG, 1.016, n=361
Week 24, USG, 1.017, n=361
Week 24, USG, 1.018, n=361
Week 24, USG, 1.019, n=362
Week 24, USG, 1.021, n=362
Week 24, USG, 1.022, n=361
Week 24, USG, 1.023, n=361
Week 24, USG, 1.025, n=362
Week 24, USG, 1.03, n=361
Week 24, USG, <=1.005, n=361
Week 24, UU, 1+, n=362
Week 24, UU, 3+, n=361
Week 24, UU, 0.1, n=362
Week 24, UU, 1, n=368
Week 24, UU, 2, n=362
Week 24, UU, 4, n=361
Week 24, UU, Neg, n=362
Week 24, UU, trace, n=3613
Week 24, UU, normal, n=365
Week 28, UB, 1+, n=341
Week 28, UB, (-), n=341
Week 28, UB, Neg, n=3432
Week 28, UOB, 1+, n=341
Week 28, UOB, (-), n=341
Week 28, UOB, Neg, n=3431
Week 28, UOB, trace, n=341
Week 28, UG, (-), n=341
Week 28, UG, 0.5, n=341
Week 28, UG, Neg, n=3432
Week 28, UK, (-), n=341
Week 28, UK, Neg, n=3432
Week 28, UK, trace, n=341
Week 28, pH, 5.5, n=341
Week 28, pH, 6, n=3412
Week 28, pH, 6.5, n=3411
Week 28, pH, 7, n=346
Week 28, pH, 7.5, n=343
Week 28, pH, 8, n=341
Week 28, UP, 1+, n=341
Week 28, UP, Neg, n=3427
Week 28, UP, trace, n=346
Week 28, USG, 1.005, n=343
Week 28, USG, 1.007, n=342
Week 28, USG, 1.008, n=341
Week 28, USG, 1.009, n=342
Week 28, USG, 1.011, n=341
Week 28, USG, 1.012, n=342
Week 28, USG, 1.013, n=341
Week 28, USG, 1.015, n=342
Week 28, USG, 1.016, n=341
Week 28, USG, 1.017, n=342
Week 28, USG, 1.018, n=341
Week 28, USG, 1.019, n=342
Week 28, USG, 1.02, n=343
Week 28, USG, 1.022, n=341
Week 28, USG, 1.023, n=342
Week 28, USG, 1.024, n=342
Week 28, USG, 1.025, n=344
Week 28, USG, 1.027, n=341
Week 28, USG, <=1.005, n=341
Week 28, UU, 1+, n=344
Week 28, UU, 0.1, n=343
Week 28, UU, 1, n=346
Week 28, UU, 2, n=342
Week 28, UU, 4, n=343
Week 28, UU, Neg, n=341
Week 28, UU, trace, n=3411
Week 28, UU, normal, n=344
Week 32, UB, (-), n=341
Week 32, UB, Neg, n=3433
Week 32, UOB, 1+, n=341
Week 32, UOB, (-), n=341
Week 32, UOB, Neg, n=3432
Week 32, UG, (-), n=341
Week 32, UG, Neg, n=3433
Week 32, UK, (-), n=341
Week 32, UK, Neg, n=3432
Week 32, UK, trace, n=341
Week 32, pH, 5, n=341
Week 32, pH, 5.5, n=342
Week 32, pH, 6, n=3414
Week 32, pH, 6.5, n=348
Week 32, pH, 7, n=348
Week 32, pH, 7.5, n=341
Week 32, UP, (-), n=341
Week 32, UP, Neg, n=3429
Week 32, UP, trace, n=344
Week 32, USG, 1.005, n=342
Week 32, USG, 1.006, n=341
Week 32, USG, 1.007, n=341
Week 32, USG, 1.01, n=344
Week 32, USG, 1.011, n=341
Week 32, USG, 1.012, n=341
Week 32, USG, 1.014, n=341
Week 32, USG, 1.015, n=344
Week 32, USG, 1.016, n=343
Week 32, USG, 1.018, n=342
Week 32, USG, 1.019, n=341
Week 32, USG, 1.02, n=346
Week 32, USG, 1.021, n=343
Week 32, USG, 1.022, n=343
Week 32, USG, 1.024, n=341
Week 32, UU, 1+, n=343
Week 32, UU, 0.1, n=342
Week 32, UU, 1, n=347
Week 32, UU, 3, n=341
Week 32, UU, 4, n=341
Week 32, UU, 8, n=341
Week 32, UU, Neg, n=341
Week 32, UU, trace, n=3412
Week 32, UU, normal, n=346
Week 36, UB, 1+, n=341
Week 36, UB, (-), n=341
Week 36, UB, Neg, n=3432
Week 36, UOB, 2+, n=342
Week 36, UOB, (-), n=341
Week 36, UOB, Neg, n=3431
Week 36, UG, (-), n=341
Week 36, UG, Neg, n=3433
Week 36, UK, 1+, n=341
Week 36, UK, (-), n=341
Week 36, UK, Neg, n=3432
Week 36, pH, 5, n=341
Week 36, pH, 5.5, n=343
Week 36, pH, 6, n=349
Week 36, pH, 6.5, n=347
Week 36, pH, 7, n=3410
Week 36, pH, 7.5, n=344
Week 36, UP, 1+, n=341
Week 36, UP, (-), n=341
Week 36, UP, Neg, n=3430
Week 36, UP, trace, n=342
Week 36, USG, 1.005, n=342
Week 36, USG, 1.007, n=341
Week 36, USG, 1.008, n=342
Week 36, USG, 1.009, n=342
Week 36, USG, 1.01, n=342
Week 36, USG, 1.011, n=341
Week 36, USG, 1.012, n=342
Week 36, USG, 1.013, n=343
Week 36, USG, 1.015, n=343
Week 36, USG, 1.016, n=342
Week 36, USG, 1.018, n=342
Week 36, USG, 1.02, n=344
Week 36, USG, 1.021, n=344
Week 36, USG, 1.023, n=341
Week 36, USG, 1.024, n=341
Week 36, USG, 1.03, n=341
Week 36, USG, <=1.005, n=341
Week 36, UU, 1+, n=342
Week 36, UU, 0.1, n=343
Week 36, UU, 1, n=347
Week 36, UU, 2, n=341
Week 36, UU, 3, n=341
Week 36, UU, 4, n=341
Week 36, UU, Neg, n=341
Week 36, UU, trace, n=3414
Week 36, UU, normal, n=344
Week 40, UB, (-), n=331
Week 40, UB, Neg, n=3332
Week 40, UOB, 2+, n=331
Week 40, UOB, 3+, n=331
Week 40, UOB, (-), n=331
Week 40, UOB, Neg, n=3330
Week 40, UG, (-), n=331
Week 40, UG, Neg, n=3332
Week 40, UK, (-), n=331
Week 40, UK, Neg, n=3331
Week 40, UK, trace, n=331
Week 40, pH, 5.5, n=334
Week 40, pH, 6, n=339
Week 40, pH, 6.5, n=336
Week 40, pH, 7, n=3310
Week 40, pH, 7.5, n=334
Week 40, UP, (-), n=331
Week 40, UP, Neg, n=3330
Week 40, UP, trace, n=332
Week 40, USG, 1.003, n=331
Week 40, USG, 1.004, n=331
Week 40, USG, 1.005, n=332
Week 40, USG, 1.006, n=331
Week 40, USG, 1.007, n=332
Week 40, USG, 1.01, n=332
Week 40, USG, 1.011, n=331
Week 40, USG, 1.012, n=333
Week 40, USG, 1.013, n=333
Week 40, USG, 1.014, n=331
Week 40, USG, 1.015, n=331
Week 40, USG, 1.016, n=333
Week 40, USG, 1.018, n=331
Week 40, USG, 1.019, n=332
Week 40, USG, 1.02, n=334
Week 40, USG, 1.022, n=331
Week 40, USG, 1.023, n=332
Week 40, USG, 1.024, n=331
Week 40, USG, 1.025, n=331
Week 40, UU, 1+, n=331
Week 40, UU, 0.1, n=333
Week 40, UU, 1, n=336
Week 40, UU, 2, n=331
Week 40, UU, 3, n=331
Week 40, UU, 4, n=331
Week 40, UU, Neg, n=331
Week 40, UU, trace, n=3313
Week 40, UU, normal, n=336
Week 44, UB, (-), n=311
Week 44, UB, Neg, n=3130
Week 44, UOB, 2+, n=312
Week 44, UOB, (-), n=311
Week 44, UOB, Neg, n=3128
Week 44, UG, (-), n=311
Week 44, UG, 0.1, n=311
Week 44, UG, Neg, n=3129
Week 44, UK, (-), n=311
Week 44, UK, Neg, n=3129
Week 44, UK, trace, n=311
Week 44, pH, 5.5, n=313
Week 44, pH, 6, n=3112
Week 44, pH, 6.5, n=318
Week 44, pH, 7, n=316
Week 44, pH, 7.5, n=312
Week 44, UP, (-), n=311
Week 44, UP, Neg, n=3127
Week 44, UP, trace, n=313
Week 44, USG, 1.005, n=313
Week 44, USG, 1.007, n=312
Week 44, USG, 1.008, n=312
Week 44, USG, 1.01, n=313
Week 44, USG, 1.011, n=313
Week 44, USG, 1.012, n=311
Week 44, USG, 1.015, n=311
Week 44, USG, 1.016, n=311
Week 44, USG, 1.017, n=313
Week 44, USG, 1.018, n=311
Week 44, USG, 1.019, n=311
Week 44, USG, 1.02, n=312
Week 44, USG, 1.021, n=312
Week 44, USG, 1.022, n=311
Week 44, USG, 1.024, n=311
Week 44, USG, 1.025, n=312
Week 44, USG, 1.027, n=311
Week 44, USG, 1.03, n=311
Week 44, UU, 1+, n=313
Week 44, UU, 2+, n=311
Week 44, UU, 0.1, n=313
Week 44, UU, 1, n=317
Week 44, UU, 2, n=311
Week 44, UU, 4, n=311
Week 44, UU, Neg, n=311
Week 44, UU, trace, n=3111
Week 44, UU, normal, n=313
Week 48, UB, (-), n=311
Week 48, UB, Neg, n=3130
Week 48, UOB, 3+, n=311
Week 48, UOB, (-), n=311
Week 48, UOB, Neg, n=3129
Week 48, UG, (-), n=311
Week 48, UG, Neg, n=3130
Week 48, UK, (-), n=311
Week 48, UK, Neg, n=3130
Week 48, pH, 5.5, n=314
Week 48, pH, 6, n=316
Week 48, pH, 6.5, n=3114
Week 48, pH, 7, n=316
Week 48, pH, 8, n=311
Week 48, UP, (-), n=311
Week 48, UP, 10, n=311
Week 48, UP, Neg, n=3126
Week 48, UP, trace, n=313
Week 48, USG, 1.005, n=311
Week 48, USG, 1.007, n=311
Week 48, USG, 1.009, n=312
Week 48, USG, 1.01, n=313
Week 48, USG, 1.011, n=312
Week 48, USG, 1.012, n=311
Week 48, USG, 1.013, n=311
Week 48, USG, 1.014, n=311
Week 48, USG, 1.015, n=314
Week 48, USG, 1.016, n=311
Week 48, USG, 1.017, n=311
Week 48, USG, 1.018, n=314
Week 48, USG, 1.019, n=313
Week 48, USG, 1.02, n=312
Week 48, USG, 1.025, n=312
Week 48, USG, 1.027, n=311
Week 48, USG, 1.03, n=311
Week 48, UU, 1+, n=312
Week 48, UU, 0.1, n=314
Week 48, UU, 1, n=313
Week 48, UU, 2, n=312
Week 48, UU, 3, n=311
Week 48, UU, Neg, n=311
Week 48, UU, trace, n=3114
Week 48, UU, normal, n=314
Withdrawal, UB, 1+, n=101
Withdrawal, UB, (-), n=101
Withdrawal, UB, Neg, n=108
Withdrawal, UOB, 1+, n=101
Withdrawal, UOB, (-), n=102
Withdrawal, UOB, Neg, n=107
Withdrawal, UG, (-), n=102
Withdrawal, UG, Neg, n=108
Withdrawal, UK, (-), n=102
Withdrawal, UK, Neg, n=108
Withdrawal, pH, 5, n=101
Withdrawal, pH, 6, n=105
Withdrawal, pH, 6.5, n=102
Withdrawal, pH, 7, n=102
Withdrawal, UP, Neg, n=105
Withdrawal, UP, trace, n=105
Withdrawal, USG, 1.002, n=101
Withdrawal, USG, 1.009, n=101
Withdrawal, USG, 1.01, n=101
Withdrawal, USG, 1.017, n=101
Withdrawal, USG, 1.018, n=101
Withdrawal, USG, 1.019, n=102
Withdrawal, USG, 1.021, n=101
Withdrawal, USG, 1.023, n=101
Withdrawal, USG, 1.025, n=101
Withdrawal, UU, 1+, n=102
Withdrawal, UU, 1, n=101
Withdrawal, UU, Neg, n=101
Withdrawal, UU, trace, n=103
Withdrawal, UU, normal, n=103
SecondaryNumber of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2

Urinalysis parameters included: UB, UOB, UG, UK, pH, UP, USG and UU. The dipstick test gives results in a semi-quantitative manner. UB was categorized as (-), negative (Neg). UOB was categorised as 1+, 2+, 3+, (-), Neg, trace. UG results were categorized as 1+, (-), 0.5, Neg. UK parameters were categorized as as (-), Neg. pH results were in the range of pH from 5-8.5 in increments of 0.5. UP was categorized as (-), Neg, trace. UU was categorized as 1+, 0.1, 1, 2, 4, Neg, trace, normal. USG results were in the range from 1.000-1.030 in increments of 0.001.

Time frame:
FU Baseline and FU Week 24
Reported as:
Number · Participants
Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2
ParticipantsEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, UB, (-)3
FU Baseline, UB, Neg.34
FU Baseline, UOB, 1+1
FU Baseline, UOB, 3+1
FU Baseline, UOB, (-)3
FU Baseline, UOB, Neg.32
FU Baseline, UG, (-)3
FU Baseline, UG, Neg34
FU Baseline, UK, (-)3
FU Baseline, UK, Neg.34
FU Baseline, pH, 51
FU Baseline, pH, 5.54
FU Baseline, pH, 610
FU Baseline, pH, 6.513
FU Baseline, pH, 78
FU Baseline, pH, 81
FU Baseline, UP, (-)1
FU Baseline, UP, 101
FU Baseline, UP, Neg27
FU Baseline, UP, trace8
FU Baseline, USG, 1.0021
FU Baseline, USG, 1.0051
FU Baseline, USG, 1.0071
FU Baseline, USG, 1.0092
FU Baseline, USG, 1.012
FU Baseline, USG, 1.0112
FU Baseline, USG, 1.0121
FU Baseline, USG, 1.0131
FU Baseline, USG, 1.0141
FU Baseline, USG, 1.0154
FU Baseline, USG, 1.0161
FU Baseline, USG, 1.0172
FU Baseline, USG, 1.0184
FU Baseline, USG, 1.0195
FU Baseline, USG, 1.022
FU Baseline, USG, 1.0211
FU Baseline, USG, 1.0241
FU Baseline, USG, 1.0253
FU Baseline, USG, 1.0271
FU Baseline, USG, 1.031
FU Baseline, UU, 1+4
FU Baseline, UU, 0.13
FU Baseline, UU, 13
FU Baseline, UU, 21
FU Baseline, UU, 31
FU Baseline, UU, Neg2
FU Baseline, UU, trace17
FU Baseline, UU, normal6
FU Week 24, UB, (-)2
FU Week 24, UB, Neg.35
FU Week 24, UOB, 1+3
FU Week 24, UOB, 3+1
FU Week 24, UOB, (-)2
FU Week 24, UOB, Neg.26
FU Week 24, UOB, Trace5
FU Week 24, UG, 1+1
FU Week 24, UG, (-)2
FU Week 24, UG, 0.21
FUWeek 24, UG, Neg33
FU Week 24, UK, (-)2
FU Week 24, UK, Neg.34
FU Week 24, UK, Trace.1
FU Week 24, pH, 54
FU Week 24, pH, 5.59
FU Week 24, pH, 67
FU Week 24, pH, 6.510
FU Week 24, pH, 73
FU Week 24, pH, 7.54
FU Week 24, UP, (-)2
FU Week 24, UP, Neg32
FU Week 24, UP, Trace3
FU Week 24, USG, 1.0041
FU Week 24, USG, 1.0052
FU Week 24, USG, 1.0082
FU Week 24, USG, 1.015
FU Week 24, USG, 1.0114
FU Week 24, USG, 1.0121
FU Week 24, USG, 1.0132
FU Week 24, USG, 1.0153
FU Week 24, USG, 1.0162
FU Week 24, USG, 1.0174
FU Week 24, USG, 1.0181
FU Week 24, USG, 1.0191
FU Week 24, USG, 1.022
FU Week 24, USG, 1.0212
FU Week 24, USG, 1.0222
FU Week 24, USG, 1.0231
FU Week 24, USG, 1.0241
FU Week 24, USG, 1.0251
FU Week 24, UU, 0.15
FU Week 24, UU, 12
FU Week 24, UU, 41
FU Week 24, UU, <1.01
FU Week 24, UU, Neg2
FU Week 24, UU, Trace18
FUWeek 24, UU, normal8
SecondaryNumber of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points

The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.

Time frame:
Screening, Antiviral Baseline, Week 12, 24, 36, 48, Withdrawal
Reported as:
Number · Participants
Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points
ParticipantsEltrombopag Dose Escalation: Part 1
Screening, normal, n=4531
Screening, abnormal-NCS, n=4514
Screening, abnormal-CS, n=450
Antiviral Baseline, normal, n=4126
Antiviral Baseline, abnormal-NCS, n=4114
Antiviral Baseline, abnormal-CS, n=411
Part 2, week 12, normal, n=3629
Part 2, week 12, abnormal-NCS, n=367
Part 2, week 12, abnormal-CS, n=360
Part 2, week 24, normal, n=3629
Part 2, week 24, abnormal-NCS, n=367
Part 2, week 24, abnormal-CS, n=360
Part 2, week 36, normal, n=3424
Part 2, week 36, abnormal-NCS, n=3410
Part 2, week 36, abnormal-CS, n=340
Part 2, week 48, normal, n=3119
Part 2, week 48, abnormal-NCS, n=3112
Part 2, week 48, abnormal-CS, n=310
Withdrawal, normal, n=1410
Withdrawal, abnormal-NCS, n=144
Withdrawal, abnormal-CS, n=140
Worst ECG post Baseline, normal, n=4124
Worst ECG post Baseline, abnormal-NCS, n=4117
Worst ECG post Baseline, abnormal-CS, n=410
SecondaryNumber of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2

The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal= all ECG parameters within accepted normal ranges. Abnormal= ECG findings outside of normal ranges. CS= ECG with a CS abnormality that meets exclusion criteria. NCS= ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.

Time frame:
FU Baseline and FU Week 24
Reported as:
Number · Participants
Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2
ParticipantsEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Baseline, normal24
FU Baseline, abnormal-NCS13
FU Baseline, abnormal-CS0
FU Week 24, normal31
FU Week 24, abnormal-NCS6
FU Week 24, abnormal-CS0
SecondaryNumber of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points

Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, withdrawal (WD)/completion (comp). Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).

Time frame:
Baseline; Week 24, Week 48, Withdrawal/Completion
Reported as:
Number · Participants
Number of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points
ParticipantsEltrombopag Dose Escalation: Part 1
Baseline, masses suspicious for HCC detected, n=450
Baseline, ascites detected, n=450
Baseline, portal vein thrombosis detected, n=450
Baseline, measureable spleen breadth, n=4543
Baseline, OCSF, n=458
Week 24, masses suspicious for HCC detected, n=361
Week 24, ascites detected, n=361
Week 24, portal vein thrombosis detected, n=360
Week 24, measureable spleen breadth, n=3634
Week 24, OCSF, n=364
Week 48, masses suspicious for HCC detected, n=290
Week 48, ascites detected, n=291
Week 48, portal vein thrombosis detected, n=290
Week 48, measureable spleen breadth, n=2929
Week 48, OCSF, n=293
WD/comp, masses suspicious for HCC detected, n=372
WD/comp, ascites detected, n=372
WD/comp, portal vein thrombosis detected, n=370
WD/comp, measureable spleen breadth, n=3737
WD/comp, OCSF, n=376
SecondaryNumber of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2

Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for hepatocellular carcinoma (HCC), ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and other clinically significant findings (OCSF).

Time frame:
FU Week 24
Reported as:
Number · Participants
Number of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2
ParticipantsEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Week 24, masses suspicious for HCC detected,1
FU Week 24, ascites detected1
FU Week 24, portal vein thrombosis detected0
FU Week 24, measureable spleen breadth36
FU Week 24, OCSF4
SecondarySpleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study

Abdominal ultrasound with doppler were taken at Baseline, Week 24, Week 48, WD/comp. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).

Time frame:
Baseline; Week 24, Week 48, Withdrawal/Completion
Reported as:
Mean · Centimeters (cm)
Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study
Centimeters (cm)Eltrombopag Dose Escalation: Part 1
Baseline, spleen length, n=4511.5 ± 2.63
Baseline, spleen width (breadth), n=434.7 ± 1.25
Week 24, spleen length, n=3611.5 ± 2.34
Week 24, spleen width (breadth), n=344.9 ± 1.21
Week 48, spleen length, n=2911.6 ± 2.27
Week 48, spleen width (breadth), n=294.5 ± 0.87
WD/comp, spleen length, n=3711.7 ± 2.67
WD/comp, spleen width (breadth), n=374.5 ± 0.93
SecondarySpleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2

Abdominal ultrasound with doppler were taken during Follow-up Period after Part 2 at FU Week 24. Questions were asked to assess masses suspicious for HCC, ascites, portal vein thrombosis detected, possiblility to measure spleen breadth, and OCSF. Spleen measurements included spleen length and spleen width (breadth).

Time frame:
FU Week 24
Reported as:
Mean · Cm
Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2
CmEltrombopag + Antiviral Therapy: Follow-up Period After Part 2
FU Week 24, spleen length11.0 ± 2.61
FU Week 24, spleen width (breadth)4.4 ± 1.32

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of study medication until follow-up visit (up to a maximun of 81 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag Dose Escalation: Part 1—0/45 (0%)0/45 (0%)
Eltrombopag + Antiviral Therapy: Part 2—3/41 (7.3%)41/41 (100%)
Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2—4/41 (9.8%)6/41 (14.6%)
Most frequent serious events
Most frequent serious events
EventEltrombopag Dose Escalation: Part 1Eltrombopag + Antiviral Therapy: Part 2Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/451/412/41
Liver injuryHepatobiliary disorders0/451/410/41
Myeloblast percentage increasedInvestigations0/451/410/41
ThrombocytosisBlood and lymphatic system disorders0/450/411/41
Herpes zosterInfections and infestations0/450/411/41
Trigeminal neuralgiaNervous system disorders0/450/411/41
Most frequent other events
Showing 10 of 50
Most frequent other events
EventEltrombopag Dose Escalation: Part 1Eltrombopag + Antiviral Therapy: Part 2Eltrombopag + Antiviral Therapy: Follow-up Period After Part 2
PyrexiaGeneral disorders0/4524/410/41
AnaemiaBlood and lymphatic system disorders0/4522/410/41
NeutropeniaBlood and lymphatic system disorders0/4517/410/41
AlopeciaSkin and subcutaneous tissue disorders0/4516/410/41
PruritusSkin and subcutaneous tissue disorders0/4514/410/41
RashSkin and subcutaneous tissue disorders0/4513/410/41
HeadacheNervous system disorders0/4513/410/41
StomatitisGastrointestinal disorders0/4512/410/41
MalaiseGeneral disorders0/4511/410/41
ArthralgiaMusculoskeletal and connective tissue disorders0/459/410/41

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag Dose Escalation: Part 1
Mean57.8 ± 9.65
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag Dose Escalation: Part 1
Female30
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eltrombopag Dose Escalation: Part 1
Asian - Japanese Heritage45
Diagnosis
Diagnosis(Participants)Eltrombopag Dose Escalation: Part 1
Chronic hepatitis C23
Liver cirrosis22
HCV genotype
HCV genotype(Participants)Eltrombopag Dose Escalation: Part 1
1a0
1b33
2a6
2b5
Others1
Child-Pugh Class
Child-Pugh Class(Participants)Eltrombopag Dose Escalation: Part 1
A (Score 5 - 6)44
B (Score 7 - 9)1
C (Score > 9)0
Number of Participants with or without previous IFN use
Number of Participants with or without previous IFN use(Participants)Eltrombopag Dose Escalation: Part 1
Naïve24
Experienced21
Baseline alanine transaminase (ALT)
Baseline alanine transaminase (ALT)(IU/L)Eltrombopag Dose Escalation: Part 1
Mean78.2 ± 47.82

2 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • GSK Investigational Site
    Aichi, 467-8602, Japan
  • GSK Investigational Site
    Fukui, 918-8503, Japan
  • GSK Investigational Site
    Fukuoka, 803-8505, Japan
  • GSK Investigational Site
    Fukuoka, 830-0011, Japan
  • GSK Investigational Site
    Gunma, 370-0829, Japan
  • GSK Investigational Site
    Hyogo, 663-8501, Japan
  • GSK Investigational Site
    Ibaraki, 317-0077, Japan
  • GSK Investigational Site
    Kagawa, 760-0017, Japan
  • GSK Investigational Site
    Kagawa, 760-8557, Japan
  • GSK Investigational Site
    Kagoshima, 899-5112, Japan
  • GSK Investigational Site
    Kanagawa, 213-8587, Japan
  • GSK Investigational Site
    Nagasaki, 856-8562, Japan
  • GSK Investigational Site
    Oita, 879-5593, Japan
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Tokyo, 105-8470, Japan
  • GSK Investigational Site
    Wakayama, 646-8558, Japan
09

References and documents

Publications

  • Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S, Kato M, Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H, Shibatoge M, Takaguchi K, Hattori T, Sata M, Koike K. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. Exp Ther Med. 2019 Jul;18(1):596-604. doi: 10.3892/etm.2019.7616. Epub 2019 May 24. PubMed 31258695 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2012
First posted
Jul 10, 2012
Start
Jul 2012
Primary completionActual
May 2014
CompletionActual
Nov 2014
Results first posted
Feb 23, 2015
Last update
Mar 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01636778
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 10, 2012
Start date
Jul 2012
Primary completion
May 2014
Completion
Nov 2014
Results posted
Feb 23, 2015
Last update
Mar 1, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion